Safety of apremilast: risk of psychical disorders
Apremilast is a new selective inhibitor of phosphodiesterase 4 (PDE4) of the class of small molecules, approved for treatment of psoriatic arthritis and psoriasis. The efficacy and safety of apremilast in the treatment of moderate to severe plaque psoriasis have been demonstrated in multicenter, ran...
Saved in:
Main Authors: | T. M. Bukatina (Author), N. Yu. Velts (Author), M. A. Darmostukova (Author), E. Yu. Pasternak (Author), T. V. Romanova (Author) |
---|---|
Format: | Book |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»,
2018-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The risk of an acute attack of angle-closure glaucoma during the treatment with modern antidepressant drugs
by: T. V. Romanova, et al.
Published: (2018) -
Rules of good laboratory practice: analysis of changes in the legislation
by: N. Yu. Velts, et al.
Published: (2018) -
Malaria and safety issues associated with antimalarial drugs
by: A. S. Kazakov, et al.
Published: (2018) -
On improving the safety of new direct acting oral anticoagulants
by: N. Yu. Velts, et al.
Published: (2018) -
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)